olanzapine


Also found in: Medical, Wikipedia.

o·lan·za·pine

 (ə-lăn′zə-pēn′)
n.
A psychotropic drug, C17H20N4S, used to treat schizophrenia, bipolar disorder, and acute psychosis.

[olan-, origin unknown + alteration of (dia)zepine, seven-member ring containing two nitrogens; see benzodiazepine.]
Translations

olanzapine

n olanzapina
References in periodicals archive ?
Here, we report a case of a 45-year-old female diagnosed with schizophrenia who developed hyponatremia soon after addition of olanzapine to the existing treatment.
Limited tenders are invited for Supply of various items: Tab Naltrexone 50mg, Tab Nortriptyline 25 mg, Tab Olanzapine 2.
Physicians should be aware that NMS with extrapyramidal syndrome could occur with olanzapine at steady state doses without recent dosage adjustments or titration.
Unlike clozapine, and despite its structural similarities, olanzapine is not usually associated with haematological suppression.
Group A patients included those who the last the drug olanzapine for the last three months.
Biopharmaceutical company Alkermes (NasdaqGS:ALKS) reported on Monday the launch of a randomized, double-blind, parallel-group study designed to evaluate the exploratory metabolic profile of ALKS 3831 when compared to olanzapine for the treatment of schizophrenia under the ENLIGHTEN pivotal programme.
Olanzapine Helps Prevent Nausea, Vomiting in Chemotherapy Patients.
Olanzapine, a thienobenzodiazepine, is an atypical antipsychotic drug with a high affinity for the serotoninergic receptors 5-HT2 and 5-HT6, and a low affinity for 5-HT3 receptors in vitro.
The treatment team started the patient on Olanzapine 15 mg nightly instead for better compliance.
Furthermore, marked improvement in TD findings arising from other antipsychotic drugs is observed when olanzapine and clozapine are used (7).
OLANZAPINE CAN CAUSE a rare but serious skin reaction that can affect other parts of the body, according to a Food and Drug Administration safety alert.
The Food and Drug Administration's review of a study that looked into the unexplained deaths of two patients days after receiving injections of the long-acting injectable formulation of the atypical antipsychotic olanzapine are "inconclusive," and no labeling changes are now recommended, the agency said.